112 related articles for article (PubMed ID: 8371203)
21. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications].
Bannwarth B; Péhourcq F; Lequen L
Therapie; 1997; 52(2):129-32. PubMed ID: 9231507
[TBL] [Abstract][Full Text] [Related]
23. Nephrotoxicity of FK-506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity.
Nielsen FT; Leyssac PP; Kemp E; Starklint H; Dieperink H
Nephrol Dial Transplant; 1995; 10(3):334-40. PubMed ID: 7540737
[TBL] [Abstract][Full Text] [Related]
24. [A comparison of osteotropic radiopharmaceuticals. II. Plasma clearance of 18F and 99mTc-EHDP (author's transl)].
Creutzig H
Rofo; 1975 Oct; 123(4):313-8. PubMed ID: 129388
[TBL] [Abstract][Full Text] [Related]
25. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
26. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of 51Cr-EDTA with 99m-Tc-DTPA slope clearance for estimation of glomerular filtration rate using the one compartment model].
Chapot C; Seifert H; Samnick S; Kirsch CM
Nuklearmedizin; 1998 Jun; 37(4):124-8. PubMed ID: 9650211
[TBL] [Abstract][Full Text] [Related]
28. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement.
Hornung N; Ellingsen T; Stengaard-Pedersen K; Poulsen JH
J Rheumatol; 2004 Dec; 31(12):2374-81. PubMed ID: 15570637
[TBL] [Abstract][Full Text] [Related]
29. [Treatment with low-dose methotrexate in chronic polyarthritis. Review of the literature].
Rau R
Z Rheumatol; 1986; 45(6):283-95. PubMed ID: 3548154
[TBL] [Abstract][Full Text] [Related]
30. [Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose of methotrexate].
Wiland P; Wiela-Hojeńska A; Swierkot J; Hurkacz M; Orzechowska-Juzwenko K; Szechiński J
Pol Arch Med Wewn; 2003 Aug; 110(2):855-62. PubMed ID: 14682224
[TBL] [Abstract][Full Text] [Related]
31. Tc-99 m diethylenetriamine-pentaacetic acid (DTPA): is it reliable for assessment of methotrexate-induced cumulative effect on renal filtration in rheumatoid arthritis patients?
Amin A; Effat D; Goher N; Ramadan B
Rheumatol Int; 2013 Dec; 33(12):3059-63. PubMed ID: 23263550
[TBL] [Abstract][Full Text] [Related]
32. Reproducibility of technetium-99m mercaptoacetyltriglycine clearance.
Piepsz A; Tondeur M; Kinthaert J; Ham HR
Eur J Nucl Med; 1996 Feb; 23(2):195-8. PubMed ID: 8925855
[TBL] [Abstract][Full Text] [Related]
33. Is low-dose methotrexate nephrotoxic? Case report and review of the literature.
Izzedine H; Launay-Vacher V; Karie S; Caramella C; de Person F; Deray G
Clin Nephrol; 2005 Oct; 64(4):315-9. PubMed ID: 16240905
[TBL] [Abstract][Full Text] [Related]
34. Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis.
Hayashi K; Sada KE; Asano Y; Asano SH; Yamamura Y; Ohashi K; Morishita M; Watanabe H; Narazaki M; Matsumoto Y; Wada J
Sci Rep; 2020 Oct; 10(1):18715. PubMed ID: 33127957
[TBL] [Abstract][Full Text] [Related]
35. The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy.
Werner RA; Beykan S; Higuchi T; Lückerath K; Weich A; Scheurlen M; Bluemel C; Herrmann K; Buck AK; Lassmann M; Lapa C; Hänscheid H
Oncotarget; 2016 Jul; 7(27):41233-41241. PubMed ID: 27259246
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of renal function in low-dose cyclosporine-treated patients using technetium-99m diaminocyclohexane: a cationic tubular excretion agent.
Sonmezoglu K; Erdil TY; Demir M; Sayman HB; Kabasakal L; Yardi OF; Ozkara H; Cem Mat M; Solanki K; Britton KE
Eur J Nucl Med; 1998 Dec; 25(12):1630-6. PubMed ID: 9871094
[TBL] [Abstract][Full Text] [Related]
37. Renal function measured by x-ray fluorescence analysis. A comparison between contrast medium clearance and non-simultaneous 51Cr-EDTA clearance.
Boijsen M; Jacobsson L; Tylén U
Acta Radiol; 1987; 28(5):581-5. PubMed ID: 2960352
[TBL] [Abstract][Full Text] [Related]
38. [Non-steroidal antirheumatic agents and nephrotoxicity].
Wegmüller E
Dtsch Med Wochenschr; 1985 Mar; 110(12):469-72. PubMed ID: 3979280
[No Abstract] [Full Text] [Related]
39. [Is methotrexate nephrotoxic? Dose-dependency, comorbidities and comedication].
Erdbrügger U; de Groot K
Z Rheumatol; 2011 Sep; 70(7):549-52. PubMed ID: 21735288
[TBL] [Abstract][Full Text] [Related]
40. [Renal excretion of methotrexate in an in vivo model in minipigs].
Cermanová J; Chládek J; Sispera L; Martínková J
Acta Medica (Hradec Kralove) Suppl; 2000; 43(2):139-47. PubMed ID: 11413676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
